nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—CSF1R—atherosclerosis	0.289	1	CbGaD
Sunitinib—ABCC4—Rosuvastatin—atherosclerosis	0.0375	0.116	CbGbCtD
Sunitinib—ABCC2—Ezetimibe—atherosclerosis	0.0223	0.0687	CbGbCtD
Sunitinib—ABCC2—Simvastatin—atherosclerosis	0.0207	0.0639	CbGbCtD
Sunitinib—ABCC2—Pravastatin—atherosclerosis	0.0203	0.0625	CbGbCtD
Sunitinib—ABCC2—Lovastatin—atherosclerosis	0.0203	0.0625	CbGbCtD
Sunitinib—ABCG2—Rosuvastatin—atherosclerosis	0.0202	0.0622	CbGbCtD
Sunitinib—ABCG2—Ezetimibe—atherosclerosis	0.0202	0.0622	CbGbCtD
Sunitinib—ABCG2—Pravastatin—atherosclerosis	0.0184	0.0565	CbGbCtD
Sunitinib—CYP3A7—Simvastatin—atherosclerosis	0.0138	0.0427	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Simvastatin—atherosclerosis	0.0138	0.0427	CbGbCtD
Sunitinib—CYP3A7—Lovastatin—atherosclerosis	0.0136	0.0418	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Lovastatin—atherosclerosis	0.0136	0.0418	CbGbCtD
Sunitinib—CYP3A5—Rosuvastatin—atherosclerosis	0.0112	0.0344	CbGbCtD
Sunitinib—CYP3A5—Simvastatin—atherosclerosis	0.0104	0.032	CbGbCtD
Sunitinib—CYP3A5—Pravastatin—atherosclerosis	0.0102	0.0313	CbGbCtD
Sunitinib—CYP3A5—Lovastatin—atherosclerosis	0.0102	0.0313	CbGbCtD
Sunitinib—ABCB1—Ezetimibe—atherosclerosis	0.00727	0.0224	CbGbCtD
Sunitinib—ABCB1—Simvastatin—atherosclerosis	0.00676	0.0208	CbGbCtD
Sunitinib—ABCB1—Pravastatin—atherosclerosis	0.00662	0.0204	CbGbCtD
Sunitinib—ABCB1—Lovastatin—atherosclerosis	0.00662	0.0204	CbGbCtD
Sunitinib—CYP3A4—Rosuvastatin—atherosclerosis	0.00436	0.0134	CbGbCtD
Sunitinib—CYP3A4—Ezetimibe—atherosclerosis	0.00436	0.0134	CbGbCtD
Sunitinib—CYP3A4—Simvastatin—atherosclerosis	0.00405	0.0125	CbGbCtD
Sunitinib—CYP3A4—Lovastatin—atherosclerosis	0.00396	0.0122	CbGbCtD
Sunitinib—CYP3A4—Pravastatin—atherosclerosis	0.00396	0.0122	CbGbCtD
Sunitinib—PRPF4—Pimozide—Ezetimibe—atherosclerosis	0.000582	0.168	CbGdCrCtD
Sunitinib—PRPF4—Lovastatin—Pravastatin—atherosclerosis	0.000577	0.167	CbGdCrCtD
Sunitinib—PRPF4—Lovastatin—Simvastatin—atherosclerosis	0.000577	0.167	CbGdCrCtD
Sunitinib—PRPF4—Fluvastatin—Rosuvastatin—atherosclerosis	0.000494	0.143	CbGdCrCtD
Sunitinib—PRPF4—Simvastatin—Pravastatin—atherosclerosis	0.000473	0.137	CbGdCrCtD
Sunitinib—PRPF4—Simvastatin—Lovastatin—atherosclerosis	0.000473	0.137	CbGdCrCtD
Sunitinib—STK11—adipose tissue—atherosclerosis	0.000402	0.004	CbGeAlD
Sunitinib—BRD4—adipose tissue—atherosclerosis	0.000402	0.004	CbGeAlD
Sunitinib—HIPK2—connective tissue—atherosclerosis	0.000401	0.00399	CbGeAlD
Sunitinib—HIPK3—connective tissue—atherosclerosis	0.000401	0.00399	CbGeAlD
Sunitinib—ALK—connective tissue—atherosclerosis	0.000401	0.00399	CbGeAlD
Sunitinib—TYRO3—connective tissue—atherosclerosis	0.000401	0.00399	CbGeAlD
Sunitinib—RPS6KA1—adipose tissue—atherosclerosis	0.000398	0.00396	CbGeAlD
Sunitinib—RIOK1—adipose tissue—atherosclerosis	0.000398	0.00396	CbGeAlD
Sunitinib—KDR—blood vessel—atherosclerosis	0.000397	0.00395	CbGeAlD
Sunitinib—PRPF4B—cardiovascular system—atherosclerosis	0.000392	0.0039	CbGeAlD
Sunitinib—MARK2—adipose tissue—atherosclerosis	0.00039	0.00388	CbGeAlD
Sunitinib—SGK3—adipose tissue—atherosclerosis	0.000387	0.00384	CbGeAlD
Sunitinib—STK39—cardiovascular system—atherosclerosis	0.000386	0.00384	CbGeAlD
Sunitinib—ICK—adipose tissue—atherosclerosis	0.000383	0.00381	CbGeAlD
Sunitinib—KIT—endothelium—atherosclerosis	0.000382	0.0038	CbGeAlD
Sunitinib—CSNK2A1—cardiovascular system—atherosclerosis	0.000381	0.00379	CbGeAlD
Sunitinib—MYLK—cardiovascular system—atherosclerosis	0.000376	0.00374	CbGeAlD
Sunitinib—ROCK1—connective tissue—atherosclerosis	0.00037	0.00368	CbGeAlD
Sunitinib—CHEK2—adipose tissue—atherosclerosis	0.00037	0.00368	CbGeAlD
Sunitinib—NUAK1—adipose tissue—atherosclerosis	0.00037	0.00368	CbGeAlD
Sunitinib—ERN1—liver—atherosclerosis	0.000368	0.00366	CbGeAlD
Sunitinib—SNRK—adipose tissue—atherosclerosis	0.000367	0.00365	CbGeAlD
Sunitinib—OXSR1—adipose tissue—atherosclerosis	0.000367	0.00365	CbGeAlD
Sunitinib—INSR—adipose tissue—atherosclerosis	0.000367	0.00365	CbGeAlD
Sunitinib—STK38—adipose tissue—atherosclerosis	0.000361	0.00359	CbGeAlD
Sunitinib—RPS6KA2—adipose tissue—atherosclerosis	0.000361	0.00359	CbGeAlD
Sunitinib—CSNK1G2—adipose tissue—atherosclerosis	0.000356	0.00354	CbGeAlD
Sunitinib—PKN1—adipose tissue—atherosclerosis	0.000356	0.00354	CbGeAlD
Sunitinib—STK17B—liver—atherosclerosis	0.000355	0.00353	CbGeAlD
Sunitinib—KIT—blood vessel—atherosclerosis	0.000352	0.0035	CbGeAlD
Sunitinib—PRPF4—adipose tissue—atherosclerosis	0.00035	0.00348	CbGeAlD
Sunitinib—HIPK3—cardiovascular system—atherosclerosis	0.000349	0.00347	CbGeAlD
Sunitinib—HIPK2—cardiovascular system—atherosclerosis	0.000349	0.00347	CbGeAlD
Sunitinib—MAP4K4—connective tissue—atherosclerosis	0.000346	0.00344	CbGeAlD
Sunitinib—PRPF4B—adipose tissue—atherosclerosis	0.000345	0.00343	CbGeAlD
Sunitinib—PDGFRB—blood vessel—atherosclerosis	0.000344	0.00342	CbGeAlD
Sunitinib—FLT3—connective tissue—atherosclerosis	0.000341	0.00339	CbGeAlD
Sunitinib—STK39—adipose tissue—atherosclerosis	0.000341	0.00339	CbGeAlD
Sunitinib—RPS6KA3—connective tissue—atherosclerosis	0.000337	0.00335	CbGeAlD
Sunitinib—CSNK2A1—adipose tissue—atherosclerosis	0.000336	0.00334	CbGeAlD
Sunitinib—DAPK3—cardiovascular system—atherosclerosis	0.000336	0.00334	CbGeAlD
Sunitinib—MAP2K1—connective tissue—atherosclerosis	0.000334	0.00332	CbGeAlD
Sunitinib—MYLK—adipose tissue—atherosclerosis	0.000332	0.0033	CbGeAlD
Sunitinib—CLK1—connective tissue—atherosclerosis	0.000328	0.00326	CbGeAlD
Sunitinib—STK17A—liver—atherosclerosis	0.000327	0.00325	CbGeAlD
Sunitinib—STK4—adipose tissue—atherosclerosis	0.000326	0.00324	CbGeAlD
Sunitinib—ROCK1—cardiovascular system—atherosclerosis	0.000322	0.0032	CbGeAlD
Sunitinib—CDK14—liver—atherosclerosis	0.000322	0.0032	CbGeAlD
Sunitinib—BMP2K—connective tissue—atherosclerosis	0.000322	0.0032	CbGeAlD
Sunitinib—PHKG2—adipose tissue—atherosclerosis	0.00032	0.00318	CbGeAlD
Sunitinib—STK24—adipose tissue—atherosclerosis	0.000318	0.00316	CbGeAlD
Sunitinib—CDK16—liver—atherosclerosis	0.000317	0.00316	CbGeAlD
Sunitinib—LATS2—liver—atherosclerosis	0.000317	0.00316	CbGeAlD
Sunitinib—DAPK2—adipose tissue—atherosclerosis	0.000315	0.00313	CbGeAlD
Sunitinib—PRKAA1—connective tissue—atherosclerosis	0.000314	0.00313	CbGeAlD
Sunitinib—DYRK1A—cardiovascular system—atherosclerosis	0.000314	0.00312	CbGeAlD
Sunitinib—PTK2B—connective tissue—atherosclerosis	0.000311	0.00309	CbGeAlD
Sunitinib—STK16—adipose tissue—atherosclerosis	0.00031	0.00308	CbGeAlD
Sunitinib—HIPK2—adipose tissue—atherosclerosis	0.000308	0.00306	CbGeAlD
Sunitinib—HIPK3—adipose tissue—atherosclerosis	0.000308	0.00306	CbGeAlD
Sunitinib—RIOK2—adipose tissue—atherosclerosis	0.000305	0.00303	CbGeAlD
Sunitinib—MAP4K1—adipose tissue—atherosclerosis	0.000302	0.003	CbGeAlD
Sunitinib—CLK4—liver—atherosclerosis	0.000302	0.003	CbGeAlD
Sunitinib—MAP4K4—cardiovascular system—atherosclerosis	0.000301	0.00299	CbGeAlD
Sunitinib—FLT3—cardiovascular system—atherosclerosis	0.000297	0.00295	CbGeAlD
Sunitinib—DAPK3—adipose tissue—atherosclerosis	0.000296	0.00294	CbGeAlD
Sunitinib—CLK2—adipose tissue—atherosclerosis	0.000293	0.00291	CbGeAlD
Sunitinib—RPS6KA3—cardiovascular system—atherosclerosis	0.000293	0.00291	CbGeAlD
Sunitinib—MAP3K2—connective tissue—atherosclerosis	0.000292	0.00291	CbGeAlD
Sunitinib—MAP4K2—adipose tissue—atherosclerosis	0.000292	0.0029	CbGeAlD
Sunitinib—DAPK1—liver—atherosclerosis	0.000291	0.00289	CbGeAlD
Sunitinib—MAP2K1—cardiovascular system—atherosclerosis	0.000291	0.00289	CbGeAlD
Sunitinib—STK3—adipose tissue—atherosclerosis	0.000288	0.00286	CbGeAlD
Sunitinib—CSNK1A1—cardiovascular system—atherosclerosis	0.000287	0.00285	CbGeAlD
Sunitinib—CLK1—cardiovascular system—atherosclerosis	0.000285	0.00284	CbGeAlD
Sunitinib—TYK2—connective tissue—atherosclerosis	0.000284	0.00283	CbGeAlD
Sunitinib—STK11—liver—atherosclerosis	0.000282	0.0028	CbGeAlD
Sunitinib—BRD4—liver—atherosclerosis	0.000282	0.0028	CbGeAlD
Sunitinib—CHEK2—Pitavastatin—Rosuvastatin—atherosclerosis	0.000281	0.0814	CbGdCrCtD
Sunitinib—CAMK2G—cardiovascular system—atherosclerosis	0.00028	0.00278	CbGeAlD
Sunitinib—RPS6KA1—liver—atherosclerosis	0.000279	0.00278	CbGeAlD
Sunitinib—RIOK1—liver—atherosclerosis	0.000279	0.00278	CbGeAlD
Sunitinib—DYRK1A—adipose tissue—atherosclerosis	0.000277	0.00275	CbGeAlD
Sunitinib—RPS6KB1—connective tissue—atherosclerosis	0.000275	0.00274	CbGeAlD
Sunitinib—TNIK—liver—atherosclerosis	0.000274	0.00272	CbGeAlD
Sunitinib—RET—connective tissue—atherosclerosis	0.000274	0.00272	CbGeAlD
Sunitinib—PRKAA1—cardiovascular system—atherosclerosis	0.000273	0.00272	CbGeAlD
Sunitinib—AXL—connective tissue—atherosclerosis	0.000273	0.00271	CbGeAlD
Sunitinib—SGK3—liver—atherosclerosis	0.000271	0.0027	CbGeAlD
Sunitinib—MERTK—adipose tissue—atherosclerosis	0.000271	0.00269	CbGeAlD
Sunitinib—PTK2B—cardiovascular system—atherosclerosis	0.00027	0.00269	CbGeAlD
Sunitinib—FLT4—cardiovascular system—atherosclerosis	0.00027	0.00268	CbGeAlD
Sunitinib—ICK—liver—atherosclerosis	0.000269	0.00267	CbGeAlD
Sunitinib—Angioedema—Rosuvastatin—atherosclerosis	0.000266	0.00252	CcSEcCtD
Sunitinib—MAP4K4—adipose tissue—atherosclerosis	0.000266	0.00264	CbGeAlD
Sunitinib—Hepatitis—Simvastatin—atherosclerosis	0.000265	0.00251	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Pravastatin—atherosclerosis	0.000265	0.0025	CcSEcCtD
Sunitinib—Stomatitis—Niacin—atherosclerosis	0.000264	0.0025	CcSEcCtD
Sunitinib—NUAK2—adipose tissue—atherosclerosis	0.000264	0.00262	CbGeAlD
Sunitinib—Acute coronary syndrome—Pravastatin—atherosclerosis	0.000263	0.00249	CcSEcCtD
Sunitinib—Flushing—Lovastatin—atherosclerosis	0.000263	0.00249	CcSEcCtD
Sunitinib—Erythema multiforme—Ezetimibe—atherosclerosis	0.000263	0.00249	CcSEcCtD
Sunitinib—MAP3K12—adipose tissue—atherosclerosis	0.000262	0.0026	CbGeAlD
Sunitinib—Neuropathy peripheral—Pravastatin—atherosclerosis	0.000262	0.00248	CcSEcCtD
Sunitinib—FGFR2—connective tissue—atherosclerosis	0.00026	0.00258	CbGeAlD
Sunitinib—Urinary tract infection—Pravastatin—atherosclerosis	0.00026	0.00246	CcSEcCtD
Sunitinib—NUAK1—liver—atherosclerosis	0.00026	0.00258	CbGeAlD
Sunitinib—JAK2—connective tissue—atherosclerosis	0.000259	0.00257	CbGeAlD
Sunitinib—RPS6KA3—adipose tissue—atherosclerosis	0.000258	0.00257	CbGeAlD
Sunitinib—Flushing—Ezetimibe—atherosclerosis	0.000258	0.00244	CcSEcCtD
Sunitinib—SNRK—liver—atherosclerosis	0.000257	0.00256	CbGeAlD
Sunitinib—INSR—liver—atherosclerosis	0.000257	0.00256	CbGeAlD
Sunitinib—OXSR1—liver—atherosclerosis	0.000257	0.00256	CbGeAlD
Sunitinib—MAP2K1—adipose tissue—atherosclerosis	0.000257	0.00255	CbGeAlD
Sunitinib—MAP2K2—cardiovascular system—atherosclerosis	0.000256	0.00255	CbGeAlD
Sunitinib—FYN—connective tissue—atherosclerosis	0.000255	0.00254	CbGeAlD
Sunitinib—Chills—Lovastatin—atherosclerosis	0.000254	0.00241	CcSEcCtD
Sunitinib—Cough—Rosuvastatin—atherosclerosis	0.000254	0.0024	CcSEcCtD
Sunitinib—RPS6KA2—liver—atherosclerosis	0.000253	0.00252	CbGeAlD
Sunitinib—STK38—liver—atherosclerosis	0.000253	0.00252	CbGeAlD
Sunitinib—CSNK1A1—adipose tissue—atherosclerosis	0.000253	0.00252	CbGeAlD
Sunitinib—Angiopathy—Ezetimibe—atherosclerosis	0.000252	0.00239	CcSEcCtD
Sunitinib—CLK1—adipose tissue—atherosclerosis	0.000252	0.0025	CbGeAlD
Sunitinib—Immune system disorder—Ezetimibe—atherosclerosis	0.000251	0.00238	CcSEcCtD
Sunitinib—Erythema multiforme—Simvastatin—atherosclerosis	0.000251	0.00237	CcSEcCtD
Sunitinib—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000251	0.00237	CcSEcCtD
Sunitinib—Alopecia—Lovastatin—atherosclerosis	0.000251	0.00237	CcSEcCtD
Sunitinib—PKN1—liver—atherosclerosis	0.000249	0.00248	CbGeAlD
Sunitinib—CSNK1G2—liver—atherosclerosis	0.000249	0.00248	CbGeAlD
Sunitinib—TBK1—cardiovascular system—atherosclerosis	0.000249	0.00248	CbGeAlD
Sunitinib—Myalgia—Rosuvastatin—atherosclerosis	0.000248	0.00235	CcSEcCtD
Sunitinib—Arthralgia—Rosuvastatin—atherosclerosis	0.000248	0.00235	CcSEcCtD
Sunitinib—TYK2—cardiovascular system—atherosclerosis	0.000247	0.00246	CbGeAlD
Sunitinib—CAMK2G—adipose tissue—atherosclerosis	0.000247	0.00245	CbGeAlD
Sunitinib—BMP2K—adipose tissue—atherosclerosis	0.000247	0.00245	CbGeAlD
Sunitinib—Flushing—Simvastatin—atherosclerosis	0.000246	0.00233	CcSEcCtD
Sunitinib—PRPF4—liver—atherosclerosis	0.000246	0.00244	CbGeAlD
Sunitinib—Alopecia—Ezetimibe—atherosclerosis	0.000246	0.00232	CcSEcCtD
Sunitinib—Haemoglobin—Niacin—atherosclerosis	0.000245	0.00231	CcSEcCtD
Sunitinib—LRRK2—adipose tissue—atherosclerosis	0.000245	0.00243	CbGeAlD
Sunitinib—Mental disorder—Ezetimibe—atherosclerosis	0.000244	0.0023	CcSEcCtD
Sunitinib—Haemorrhage—Niacin—atherosclerosis	0.000243	0.0023	CcSEcCtD
Sunitinib—Hepatitis—Niacin—atherosclerosis	0.000243	0.0023	CcSEcCtD
Sunitinib—Flatulence—Lovastatin—atherosclerosis	0.000243	0.0023	CcSEcCtD
Sunitinib—PRPF4B—liver—atherosclerosis	0.000242	0.00241	CbGeAlD
Sunitinib—Hypoaesthesia—Niacin—atherosclerosis	0.000242	0.00229	CcSEcCtD
Sunitinib—Malnutrition—Ezetimibe—atherosclerosis	0.000242	0.00229	CcSEcCtD
Sunitinib—Erythema—Ezetimibe—atherosclerosis	0.000242	0.00229	CcSEcCtD
Sunitinib—Dysgeusia—Lovastatin—atherosclerosis	0.000242	0.00229	CcSEcCtD
Sunitinib—PRKAA1—adipose tissue—atherosclerosis	0.000241	0.0024	CbGeAlD
Sunitinib—FLT1—connective tissue—atherosclerosis	0.000241	0.0024	CbGeAlD
Sunitinib—Oedema peripheral—Niacin—atherosclerosis	0.00024	0.00227	CcSEcCtD
Sunitinib—Hepatitis—Pravastatin—atherosclerosis	0.00024	0.00227	CcSEcCtD
Sunitinib—RPS6KB1—cardiovascular system—atherosclerosis	0.00024	0.00238	CbGeAlD
Sunitinib—Back pain—Lovastatin—atherosclerosis	0.000239	0.00226	CcSEcCtD
Sunitinib—Hypoaesthesia—Pravastatin—atherosclerosis	0.000239	0.00226	CcSEcCtD
Sunitinib—Flatulence—Ezetimibe—atherosclerosis	0.000239	0.00226	CcSEcCtD
Sunitinib—PTK2B—adipose tissue—atherosclerosis	0.000238	0.00237	CbGeAlD
Sunitinib—FGR—cardiovascular system—atherosclerosis	0.000238	0.00237	CbGeAlD
Sunitinib—Chills—Simvastatin—atherosclerosis	0.000238	0.00225	CcSEcCtD
Sunitinib—FLT4—adipose tissue—atherosclerosis	0.000238	0.00236	CbGeAlD
Sunitinib—Muscle spasms—Lovastatin—atherosclerosis	0.000237	0.00224	CcSEcCtD
Sunitinib—AXL—cardiovascular system—atherosclerosis	0.000237	0.00236	CbGeAlD
Sunitinib—Infection—Rosuvastatin—atherosclerosis	0.000236	0.00223	CcSEcCtD
Sunitinib—CSNK2A1—liver—atherosclerosis	0.000236	0.00234	CbGeAlD
Sunitinib—CSNK1E—adipose tissue—atherosclerosis	0.000235	0.00233	CbGeAlD
Sunitinib—FGFR1—adipose tissue—atherosclerosis	0.000235	0.00233	CbGeAlD
Sunitinib—Alopecia—Simvastatin—atherosclerosis	0.000234	0.00222	CcSEcCtD
Sunitinib—Back pain—Ezetimibe—atherosclerosis	0.000234	0.00221	CcSEcCtD
Sunitinib—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000233	0.0022	CcSEcCtD
Sunitinib—MYLK—liver—atherosclerosis	0.000233	0.00231	CbGeAlD
Sunitinib—Muscle spasms—Ezetimibe—atherosclerosis	0.000233	0.0022	CcSEcCtD
Sunitinib—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000233	0.0022	CcSEcCtD
Sunitinib—Mental disorder—Simvastatin—atherosclerosis	0.000232	0.0022	CcSEcCtD
Sunitinib—IRAK4—adipose tissue—atherosclerosis	0.000231	0.0023	CbGeAlD
Sunitinib—Erythema—Simvastatin—atherosclerosis	0.000231	0.00218	CcSEcCtD
Sunitinib—YES1—connective tissue—atherosclerosis	0.00023	0.00229	CbGeAlD
Sunitinib—STK4—liver—atherosclerosis	0.000228	0.00227	CbGeAlD
Sunitinib—Eye disorder—Niacin—atherosclerosis	0.000228	0.00215	CcSEcCtD
Sunitinib—Flatulence—Simvastatin—atherosclerosis	0.000227	0.00215	CcSEcCtD
Sunitinib—TAOK3—connective tissue—atherosclerosis	0.000227	0.00226	CbGeAlD
Sunitinib—Erythema multiforme—Pravastatin—atherosclerosis	0.000227	0.00214	CcSEcCtD
Sunitinib—FGFR2—cardiovascular system—atherosclerosis	0.000226	0.00225	CbGeAlD
Sunitinib—Dysgeusia—Simvastatin—atherosclerosis	0.000226	0.00214	CcSEcCtD
Sunitinib—Flushing—Niacin—atherosclerosis	0.000226	0.00214	CcSEcCtD
Sunitinib—ULK3—adipose tissue—atherosclerosis	0.000226	0.00225	CbGeAlD
Sunitinib—MAP2K2—adipose tissue—atherosclerosis	0.000226	0.00225	CbGeAlD
Sunitinib—PDGFRA—connective tissue—atherosclerosis	0.000226	0.00225	CbGeAlD
Sunitinib—Angioedema—Lovastatin—atherosclerosis	0.000226	0.00213	CcSEcCtD
Sunitinib—JAK2—cardiovascular system—atherosclerosis	0.000225	0.00224	CbGeAlD
Sunitinib—PHKG2—liver—atherosclerosis	0.000224	0.00223	CbGeAlD
Sunitinib—MAP3K2—adipose tissue—atherosclerosis	0.000224	0.00223	CbGeAlD
Sunitinib—Anaemia—Ezetimibe—atherosclerosis	0.000224	0.00212	CcSEcCtD
Sunitinib—STK24—liver—atherosclerosis	0.000223	0.00222	CbGeAlD
Sunitinib—Flushing—Pravastatin—atherosclerosis	0.000223	0.0021	CcSEcCtD
Sunitinib—Cardiac disorder—Pravastatin—atherosclerosis	0.000223	0.0021	CcSEcCtD
Sunitinib—MAP3K7—adipose tissue—atherosclerosis	0.000222	0.00221	CbGeAlD
Sunitinib—FYN—cardiovascular system—atherosclerosis	0.000222	0.00221	CbGeAlD
Sunitinib—Muscle spasms—Simvastatin—atherosclerosis	0.000222	0.0021	CcSEcCtD
Sunitinib—Angioedema—Ezetimibe—atherosclerosis	0.000221	0.00209	CcSEcCtD
Sunitinib—Angiopathy—Niacin—atherosclerosis	0.000221	0.00209	CcSEcCtD
Sunitinib—Leukopenia—Lovastatin—atherosclerosis	0.000221	0.00209	CcSEcCtD
Sunitinib—TBK1—adipose tissue—atherosclerosis	0.00022	0.00218	CbGeAlD
Sunitinib—Chills—Niacin—atherosclerosis	0.000218	0.00207	CcSEcCtD
Sunitinib—TYK2—adipose tissue—atherosclerosis	0.000218	0.00217	CbGeAlD
Sunitinib—Arrhythmia—Niacin—atherosclerosis	0.000218	0.00206	CcSEcCtD
Sunitinib—STK16—liver—atherosclerosis	0.000217	0.00216	CbGeAlD
Sunitinib—MAP3K3—cardiovascular system—atherosclerosis	0.000217	0.00216	CbGeAlD
Sunitinib—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000217	0.00205	CcSEcCtD
Sunitinib—HIPK2—liver—atherosclerosis	0.000216	0.00215	CbGeAlD
Sunitinib—HIPK3—liver—atherosclerosis	0.000216	0.00215	CbGeAlD
Sunitinib—IRAK1—adipose tissue—atherosclerosis	0.000215	0.00214	CbGeAlD
Sunitinib—Alopecia—Niacin—atherosclerosis	0.000215	0.00204	CcSEcCtD
Sunitinib—Chills—Pravastatin—atherosclerosis	0.000215	0.00203	CcSEcCtD
Sunitinib—Insomnia—Rosuvastatin—atherosclerosis	0.000215	0.00203	CcSEcCtD
Sunitinib—Arrhythmia—Pravastatin—atherosclerosis	0.000214	0.00203	CcSEcCtD
Sunitinib—RIOK2—liver—atherosclerosis	0.000214	0.00212	CbGeAlD
Sunitinib—TNK1—liver—atherosclerosis	0.000214	0.00212	CbGeAlD
Sunitinib—Paraesthesia—Rosuvastatin—atherosclerosis	0.000213	0.00202	CcSEcCtD
Sunitinib—Anaemia—Simvastatin—atherosclerosis	0.000213	0.00202	CcSEcCtD
Sunitinib—Erythema—Niacin—atherosclerosis	0.000212	0.002	CcSEcCtD
Sunitinib—Malnutrition—Niacin—atherosclerosis	0.000212	0.002	CcSEcCtD
Sunitinib—Alopecia—Pravastatin—atherosclerosis	0.000212	0.002	CcSEcCtD
Sunitinib—RPS6KB1—adipose tissue—atherosclerosis	0.000211	0.0021	CbGeAlD
Sunitinib—Cough—Ezetimibe—atherosclerosis	0.000211	0.002	CcSEcCtD
Sunitinib—Angioedema—Simvastatin—atherosclerosis	0.000211	0.002	CcSEcCtD
Sunitinib—Arthralgia—Lovastatin—atherosclerosis	0.00021	0.00199	CcSEcCtD
Sunitinib—Chest pain—Lovastatin—atherosclerosis	0.00021	0.00199	CcSEcCtD
Sunitinib—Myalgia—Lovastatin—atherosclerosis	0.00021	0.00199	CcSEcCtD
Sunitinib—FGR—adipose tissue—atherosclerosis	0.00021	0.00209	CbGeAlD
Sunitinib—FLT1—cardiovascular system—atherosclerosis	0.00021	0.00208	CbGeAlD
Sunitinib—Dyspepsia—Rosuvastatin—atherosclerosis	0.000209	0.00198	CcSEcCtD
Sunitinib—AXL—adipose tissue—atherosclerosis	0.000209	0.00208	CbGeAlD
Sunitinib—Hypertension—Ezetimibe—atherosclerosis	0.000209	0.00198	CcSEcCtD
Sunitinib—Flatulence—Niacin—atherosclerosis	0.000209	0.00198	CcSEcCtD
Sunitinib—DAPK3—liver—atherosclerosis	0.000207	0.00206	CbGeAlD
Sunitinib—Leukopenia—Simvastatin—atherosclerosis	0.000207	0.00195	CcSEcCtD
Sunitinib—Chest pain—Ezetimibe—atherosclerosis	0.000206	0.00195	CcSEcCtD
Sunitinib—Myalgia—Ezetimibe—atherosclerosis	0.000206	0.00195	CcSEcCtD
Sunitinib—Arthralgia—Ezetimibe—atherosclerosis	0.000206	0.00195	CcSEcCtD
Sunitinib—Flatulence—Pravastatin—atherosclerosis	0.000206	0.00195	CcSEcCtD
Sunitinib—CLK2—liver—atherosclerosis	0.000206	0.00204	CbGeAlD
Sunitinib—Dry mouth—Lovastatin—atherosclerosis	0.000205	0.00194	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000205	0.00194	CcSEcCtD
Sunitinib—MAP4K2—liver—atherosclerosis	0.000205	0.00203	CbGeAlD
Sunitinib—Dysgeusia—Pravastatin—atherosclerosis	0.000204	0.00193	CcSEcCtD
Sunitinib—Muscle spasms—Niacin—atherosclerosis	0.000204	0.00193	CcSEcCtD
Sunitinib—KDR—connective tissue—atherosclerosis	0.000204	0.00203	CbGeAlD
Sunitinib—Constipation—Rosuvastatin—atherosclerosis	0.000203	0.00192	CcSEcCtD
Sunitinib—Pain—Rosuvastatin—atherosclerosis	0.000203	0.00192	CcSEcCtD
Sunitinib—STK3—liver—atherosclerosis	0.000202	0.00201	CbGeAlD
Sunitinib—Dry mouth—Ezetimibe—atherosclerosis	0.000202	0.00191	CcSEcCtD
Sunitinib—SLK—adipose tissue—atherosclerosis	0.000201	0.002	CbGeAlD
Sunitinib—Muscle spasms—Pravastatin—atherosclerosis	0.000201	0.0019	CcSEcCtD
Sunitinib—Infection—Lovastatin—atherosclerosis	0.0002	0.00189	CcSEcCtD
Sunitinib—FGFR2—adipose tissue—atherosclerosis	0.000199	0.00198	CbGeAlD
Sunitinib—ROCK1—liver—atherosclerosis	0.000199	0.00198	CbGeAlD
Sunitinib—CSF1R—connective tissue—atherosclerosis	0.000199	0.00198	CbGeAlD
Sunitinib—STK10—cardiovascular system—atherosclerosis	0.000198	0.00197	CbGeAlD
Sunitinib—JAK2—adipose tissue—atherosclerosis	0.000198	0.00197	CbGeAlD
Sunitinib—TAOK3—cardiovascular system—atherosclerosis	0.000198	0.00197	CbGeAlD
Sunitinib—Thrombocytopenia—Lovastatin—atherosclerosis	0.000197	0.00187	CcSEcCtD
Sunitinib—Arthralgia—Simvastatin—atherosclerosis	0.000197	0.00186	CcSEcCtD
Sunitinib—Chest pain—Simvastatin—atherosclerosis	0.000197	0.00186	CcSEcCtD
Sunitinib—Myalgia—Simvastatin—atherosclerosis	0.000197	0.00186	CcSEcCtD
Sunitinib—PDGFRA—cardiovascular system—atherosclerosis	0.000196	0.00195	CbGeAlD
Sunitinib—Infection—Ezetimibe—atherosclerosis	0.000196	0.00186	CcSEcCtD
Sunitinib—FYN—adipose tissue—atherosclerosis	0.000196	0.00195	CbGeAlD
Sunitinib—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000194	0.00184	CcSEcCtD
Sunitinib—DYRK1A—liver—atherosclerosis	0.000194	0.00193	CbGeAlD
Sunitinib—Nervous system disorder—Ezetimibe—atherosclerosis	0.000194	0.00183	CcSEcCtD
Sunitinib—Angioedema—Niacin—atherosclerosis	0.000194	0.00183	CcSEcCtD
Sunitinib—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000193	0.00183	CcSEcCtD
Sunitinib—Anaemia—Pravastatin—atherosclerosis	0.000193	0.00182	CcSEcCtD
Sunitinib—Anorexia—Lovastatin—atherosclerosis	0.000192	0.00182	CcSEcCtD
Sunitinib—Skin disorder—Ezetimibe—atherosclerosis	0.000192	0.00182	CcSEcCtD
Sunitinib—MAP3K3—adipose tissue—atherosclerosis	0.000191	0.0019	CbGeAlD
Sunitinib—MAP4K5—adipose tissue—atherosclerosis	0.000191	0.0019	CbGeAlD
Sunitinib—Angioedema—Pravastatin—atherosclerosis	0.000191	0.0018	CcSEcCtD
Sunitinib—MERTK—liver—atherosclerosis	0.00019	0.00189	CbGeAlD
Sunitinib—Leukopenia—Niacin—atherosclerosis	0.00019	0.00179	CcSEcCtD
Sunitinib—Oedema—Simvastatin—atherosclerosis	0.000188	0.00178	CcSEcCtD
Sunitinib—Abdominal pain—Rosuvastatin—atherosclerosis	0.000188	0.00178	CcSEcCtD
Sunitinib—Infection—Simvastatin—atherosclerosis	0.000187	0.00177	CcSEcCtD
Sunitinib—Leukopenia—Pravastatin—atherosclerosis	0.000187	0.00177	CcSEcCtD
Sunitinib—MAP4K4—liver—atherosclerosis	0.000186	0.00185	CbGeAlD
Sunitinib—Cough—Niacin—atherosclerosis	0.000185	0.00175	CcSEcCtD
Sunitinib—NUAK2—liver—atherosclerosis	0.000185	0.00184	CbGeAlD
Sunitinib—FLT1—adipose tissue—atherosclerosis	0.000185	0.00184	CbGeAlD
Sunitinib—Thrombocytopenia—Simvastatin—atherosclerosis	0.000184	0.00174	CcSEcCtD
Sunitinib—FLT3—liver—atherosclerosis	0.000184	0.00183	CbGeAlD
Sunitinib—MAP3K12—liver—atherosclerosis	0.000184	0.00183	CbGeAlD
Sunitinib—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000184	0.00174	CcSEcCtD
Sunitinib—EPHB6—adipose tissue—atherosclerosis	0.000183	0.00182	CbGeAlD
Sunitinib—Insomnia—Lovastatin—atherosclerosis	0.000182	0.00172	CcSEcCtD
Sunitinib—Cough—Pravastatin—atherosclerosis	0.000182	0.00172	CcSEcCtD
Sunitinib—RPS6KA3—liver—atherosclerosis	0.000181	0.0018	CbGeAlD
Sunitinib—Paraesthesia—Lovastatin—atherosclerosis	0.000181	0.00171	CcSEcCtD
Sunitinib—KIT—connective tissue—atherosclerosis	0.000181	0.00179	CbGeAlD
Sunitinib—Myalgia—Niacin—atherosclerosis	0.00018	0.00171	CcSEcCtD
Sunitinib—Arthralgia—Niacin—atherosclerosis	0.00018	0.00171	CcSEcCtD
Sunitinib—Hypertension—Pravastatin—atherosclerosis	0.00018	0.0017	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00018	0.0017	CcSEcCtD
Sunitinib—MAP2K1—liver—atherosclerosis	0.00018	0.00179	CbGeAlD
Sunitinib—Anorexia—Simvastatin—atherosclerosis	0.00018	0.0017	CcSEcCtD
Sunitinib—Dyspnoea—Lovastatin—atherosclerosis	0.00018	0.0017	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000179	0.0017	CcSEcCtD
Sunitinib—Insomnia—Ezetimibe—atherosclerosis	0.000179	0.00169	CcSEcCtD
Sunitinib—Chest pain—Pravastatin—atherosclerosis	0.000178	0.00168	CcSEcCtD
Sunitinib—Myalgia—Pravastatin—atherosclerosis	0.000178	0.00168	CcSEcCtD
Sunitinib—Arthralgia—Pravastatin—atherosclerosis	0.000178	0.00168	CcSEcCtD
Sunitinib—CSNK1A1—liver—atherosclerosis	0.000178	0.00177	CbGeAlD
Sunitinib—Paraesthesia—Ezetimibe—atherosclerosis	0.000177	0.00168	CcSEcCtD
Sunitinib—Dyspepsia—Lovastatin—atherosclerosis	0.000177	0.00168	CcSEcCtD
Sunitinib—KDR—cardiovascular system—atherosclerosis	0.000177	0.00176	CbGeAlD
Sunitinib—MAP2K5—cardiovascular system—atherosclerosis	0.000177	0.00176	CbGeAlD
Sunitinib—YES1—adipose tissue—atherosclerosis	0.000177	0.00176	CbGeAlD
Sunitinib—Dry mouth—Niacin—atherosclerosis	0.000176	0.00167	CcSEcCtD
Sunitinib—CLK1—liver—atherosclerosis	0.000176	0.00175	CbGeAlD
Sunitinib—PDGFRB—connective tissue—atherosclerosis	0.000176	0.00175	CbGeAlD
Sunitinib—Dyspnoea—Ezetimibe—atherosclerosis	0.000176	0.00167	CcSEcCtD
Sunitinib—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000175	0.00166	CcSEcCtD
Sunitinib—Decreased appetite—Lovastatin—atherosclerosis	0.000175	0.00166	CcSEcCtD
Sunitinib—STK10—adipose tissue—atherosclerosis	0.000175	0.00174	CbGeAlD
Sunitinib—TAOK3—adipose tissue—atherosclerosis	0.000174	0.00173	CbGeAlD
Sunitinib—Dyspepsia—Ezetimibe—atherosclerosis	0.000174	0.00164	CcSEcCtD
Sunitinib—Fatigue—Lovastatin—atherosclerosis	0.000174	0.00164	CcSEcCtD
Sunitinib—PDGFRA—adipose tissue—atherosclerosis	0.000173	0.00172	CbGeAlD
Sunitinib—BMP2K—liver—atherosclerosis	0.000173	0.00172	CbGeAlD
Sunitinib—CAMK2G—liver—atherosclerosis	0.000173	0.00172	CbGeAlD
Sunitinib—CSF1R—cardiovascular system—atherosclerosis	0.000173	0.00172	CbGeAlD
Sunitinib—Oedema—Niacin—atherosclerosis	0.000173	0.00164	CcSEcCtD
Sunitinib—Constipation—Lovastatin—atherosclerosis	0.000172	0.00163	CcSEcCtD
Sunitinib—Pain—Lovastatin—atherosclerosis	0.000172	0.00163	CcSEcCtD
Sunitinib—Decreased appetite—Ezetimibe—atherosclerosis	0.000172	0.00162	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000172	0.00162	CcSEcCtD
Sunitinib—LRRK2—liver—atherosclerosis	0.000172	0.00171	CbGeAlD
Sunitinib—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000171	0.00161	CcSEcCtD
Sunitinib—Asthenia—Rosuvastatin—atherosclerosis	0.000171	0.00161	CcSEcCtD
Sunitinib—Insomnia—Simvastatin—atherosclerosis	0.00017	0.00161	CcSEcCtD
Sunitinib—Oedema—Pravastatin—atherosclerosis	0.00017	0.00161	CcSEcCtD
Sunitinib—Fatigue—Ezetimibe—atherosclerosis	0.00017	0.00161	CcSEcCtD
Sunitinib—Shock—Niacin—atherosclerosis	0.00017	0.00161	CcSEcCtD
Sunitinib—Infection—Pravastatin—atherosclerosis	0.000169	0.0016	CcSEcCtD
Sunitinib—Paraesthesia—Simvastatin—atherosclerosis	0.000169	0.0016	CcSEcCtD
Sunitinib—PRKAA1—liver—atherosclerosis	0.000169	0.00168	CbGeAlD
Sunitinib—Pain—Ezetimibe—atherosclerosis	0.000169	0.0016	CcSEcCtD
Sunitinib—Constipation—Ezetimibe—atherosclerosis	0.000169	0.0016	CcSEcCtD
Sunitinib—Pruritus—Rosuvastatin—atherosclerosis	0.000168	0.00159	CcSEcCtD
Sunitinib—Skin disorder—Niacin—atherosclerosis	0.000168	0.00159	CcSEcCtD
Sunitinib—Dyspnoea—Simvastatin—atherosclerosis	0.000168	0.00159	CcSEcCtD
Sunitinib—PTK2B—liver—atherosclerosis	0.000167	0.00166	CbGeAlD
Sunitinib—FLT4—liver—atherosclerosis	0.000167	0.00166	CbGeAlD
Sunitinib—Thrombocytopenia—Pravastatin—atherosclerosis	0.000167	0.00158	CcSEcCtD
Sunitinib—Dyspepsia—Simvastatin—atherosclerosis	0.000166	0.00157	CcSEcCtD
Sunitinib—Anorexia—Niacin—atherosclerosis	0.000165	0.00156	CcSEcCtD
Sunitinib—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000165	0.00156	CcSEcCtD
Sunitinib—CSNK1E—liver—atherosclerosis	0.000165	0.00164	CbGeAlD
Sunitinib—FGFR1—liver—atherosclerosis	0.000165	0.00164	CbGeAlD
Sunitinib—Decreased appetite—Simvastatin—atherosclerosis	0.000164	0.00155	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000163	0.00154	CcSEcCtD
Sunitinib—Diarrhoea—Rosuvastatin—atherosclerosis	0.000163	0.00154	CcSEcCtD
Sunitinib—Fatigue—Simvastatin—atherosclerosis	0.000162	0.00154	CcSEcCtD
Sunitinib—Anorexia—Pravastatin—atherosclerosis	0.000162	0.00154	CcSEcCtD
Sunitinib—IRAK4—liver—atherosclerosis	0.000162	0.00161	CbGeAlD
Sunitinib—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000162	0.00153	CcSEcCtD
Sunitinib—Constipation—Simvastatin—atherosclerosis	0.000161	0.00152	CcSEcCtD
Sunitinib—Pain—Simvastatin—atherosclerosis	0.000161	0.00152	CcSEcCtD
Sunitinib—Body temperature increased—Lovastatin—atherosclerosis	0.000159	0.00151	CcSEcCtD
Sunitinib—Abdominal pain—Lovastatin—atherosclerosis	0.000159	0.00151	CcSEcCtD
Sunitinib—MAP2K2—liver—atherosclerosis	0.000158	0.00157	CbGeAlD
Sunitinib—ULK3—liver—atherosclerosis	0.000158	0.00157	CbGeAlD
Sunitinib—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000158	0.00149	CcSEcCtD
Sunitinib—MAP3K2—liver—atherosclerosis	0.000157	0.00156	CbGeAlD
Sunitinib—Dizziness—Rosuvastatin—atherosclerosis	0.000157	0.00149	CcSEcCtD
Sunitinib—KIT—cardiovascular system—atherosclerosis	0.000157	0.00156	CbGeAlD
Sunitinib—Insomnia—Niacin—atherosclerosis	0.000156	0.00148	CcSEcCtD
Sunitinib—KDR—adipose tissue—atherosclerosis	0.000156	0.00155	CbGeAlD
Sunitinib—MAP2K5—adipose tissue—atherosclerosis	0.000156	0.00155	CbGeAlD
Sunitinib—Abdominal pain—Ezetimibe—atherosclerosis	0.000156	0.00148	CcSEcCtD
Sunitinib—Body temperature increased—Ezetimibe—atherosclerosis	0.000156	0.00148	CcSEcCtD
Sunitinib—MAP3K7—liver—atherosclerosis	0.000156	0.00155	CbGeAlD
Sunitinib—Paraesthesia—Niacin—atherosclerosis	0.000155	0.00147	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000155	0.00147	CcSEcCtD
Sunitinib—Dyspnoea—Niacin—atherosclerosis	0.000154	0.00146	CcSEcCtD
Sunitinib—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000154	0.00146	CcSEcCtD
Sunitinib—Insomnia—Pravastatin—atherosclerosis	0.000154	0.00146	CcSEcCtD
Sunitinib—TBK1—liver—atherosclerosis	0.000154	0.00153	CbGeAlD
Sunitinib—PDGFRB—cardiovascular system—atherosclerosis	0.000153	0.00153	CbGeAlD
Sunitinib—TYK2—liver—atherosclerosis	0.000153	0.00152	CbGeAlD
Sunitinib—Paraesthesia—Pravastatin—atherosclerosis	0.000153	0.00145	CcSEcCtD
Sunitinib—CSF1R—adipose tissue—atherosclerosis	0.000153	0.00152	CbGeAlD
Sunitinib—Dyspepsia—Niacin—atherosclerosis	0.000152	0.00144	CcSEcCtD
Sunitinib—Dyspnoea—Pravastatin—atherosclerosis	0.000152	0.00144	CcSEcCtD
Sunitinib—IRAK1—liver—atherosclerosis	0.000151	0.0015	CbGeAlD
Sunitinib—Decreased appetite—Niacin—atherosclerosis	0.00015	0.00142	CcSEcCtD
Sunitinib—Dyspepsia—Pravastatin—atherosclerosis	0.00015	0.00142	CcSEcCtD
Sunitinib—Rash—Rosuvastatin—atherosclerosis	0.00015	0.00142	CcSEcCtD
Sunitinib—Dermatitis—Rosuvastatin—atherosclerosis	0.00015	0.00142	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Niacin—atherosclerosis	0.000149	0.00141	CcSEcCtD
Sunitinib—Body temperature increased—Simvastatin—atherosclerosis	0.000149	0.00141	CcSEcCtD
Sunitinib—Abdominal pain—Simvastatin—atherosclerosis	0.000149	0.00141	CcSEcCtD
Sunitinib—Headache—Rosuvastatin—atherosclerosis	0.000149	0.00141	CcSEcCtD
Sunitinib—Hypersensitivity—Lovastatin—atherosclerosis	0.000148	0.0014	CcSEcCtD
Sunitinib—RPS6KB1—liver—atherosclerosis	0.000148	0.00147	CbGeAlD
Sunitinib—Decreased appetite—Pravastatin—atherosclerosis	0.000148	0.0014	CcSEcCtD
Sunitinib—Pain—Niacin—atherosclerosis	0.000148	0.0014	CcSEcCtD
Sunitinib—FGR—liver—atherosclerosis	0.000147	0.00146	CbGeAlD
Sunitinib—Fatigue—Pravastatin—atherosclerosis	0.000147	0.00139	CcSEcCtD
Sunitinib—AXL—liver—atherosclerosis	0.000147	0.00146	CbGeAlD
Sunitinib—Pain—Pravastatin—atherosclerosis	0.000146	0.00138	CcSEcCtD
Sunitinib—Constipation—Pravastatin—atherosclerosis	0.000146	0.00138	CcSEcCtD
Sunitinib—Hypersensitivity—Ezetimibe—atherosclerosis	0.000146	0.00138	CcSEcCtD
Sunitinib—Asthenia—Lovastatin—atherosclerosis	0.000145	0.00137	CcSEcCtD
Sunitinib—Pruritus—Lovastatin—atherosclerosis	0.000143	0.00135	CcSEcCtD
Sunitinib—Asthenia—Ezetimibe—atherosclerosis	0.000142	0.00134	CcSEcCtD
Sunitinib—Gastrointestinal pain—Niacin—atherosclerosis	0.000141	0.00134	CcSEcCtD
Sunitinib—Nausea—Rosuvastatin—atherosclerosis	0.000141	0.00134	CcSEcCtD
Sunitinib—SLK—liver—atherosclerosis	0.000141	0.0014	CbGeAlD
Sunitinib—CYP3A7—liver—atherosclerosis	0.000141	0.0014	CbGeAlD
Sunitinib—FGFR2—liver—atherosclerosis	0.00014	0.00139	CbGeAlD
Sunitinib—Pruritus—Ezetimibe—atherosclerosis	0.00014	0.00132	CcSEcCtD
Sunitinib—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000139	0.00132	CcSEcCtD
Sunitinib—JAK2—liver—atherosclerosis	0.000139	0.00138	CbGeAlD
Sunitinib—Hypersensitivity—Simvastatin—atherosclerosis	0.000139	0.00131	CcSEcCtD
Sunitinib—KIT—adipose tissue—atherosclerosis	0.000139	0.00138	CbGeAlD
Sunitinib—Diarrhoea—Lovastatin—atherosclerosis	0.000138	0.0013	CcSEcCtD
Sunitinib—FYN—liver—atherosclerosis	0.000137	0.00136	CbGeAlD
Sunitinib—Abdominal pain—Niacin—atherosclerosis	0.000137	0.00129	CcSEcCtD
Sunitinib—Body temperature increased—Niacin—atherosclerosis	0.000137	0.00129	CcSEcCtD
Sunitinib—PDGFRB—adipose tissue—atherosclerosis	0.000135	0.00135	CbGeAlD
Sunitinib—Asthenia—Simvastatin—atherosclerosis	0.000135	0.00128	CcSEcCtD
Sunitinib—Diarrhoea—Ezetimibe—atherosclerosis	0.000135	0.00128	CcSEcCtD
Sunitinib—Abdominal pain—Pravastatin—atherosclerosis	0.000135	0.00127	CcSEcCtD
Sunitinib—Body temperature increased—Pravastatin—atherosclerosis	0.000135	0.00127	CcSEcCtD
Sunitinib—MAP3K3—liver—atherosclerosis	0.000134	0.00133	CbGeAlD
Sunitinib—MAP4K5—liver—atherosclerosis	0.000134	0.00133	CbGeAlD
Sunitinib—Pruritus—Simvastatin—atherosclerosis	0.000133	0.00126	CcSEcCtD
Sunitinib—Dizziness—Lovastatin—atherosclerosis	0.000133	0.00126	CcSEcCtD
Sunitinib—Dizziness—Ezetimibe—atherosclerosis	0.000131	0.00124	CcSEcCtD
Sunitinib—FLT1—liver—atherosclerosis	0.00013	0.00129	CbGeAlD
Sunitinib—Diarrhoea—Simvastatin—atherosclerosis	0.000129	0.00122	CcSEcCtD
Sunitinib—Vomiting—Lovastatin—atherosclerosis	0.000128	0.00121	CcSEcCtD
Sunitinib—Hypersensitivity—Niacin—atherosclerosis	0.000127	0.00121	CcSEcCtD
Sunitinib—Rash—Lovastatin—atherosclerosis	0.000127	0.0012	CcSEcCtD
Sunitinib—Dermatitis—Lovastatin—atherosclerosis	0.000127	0.0012	CcSEcCtD
Sunitinib—Headache—Lovastatin—atherosclerosis	0.000126	0.00119	CcSEcCtD
Sunitinib—Vomiting—Ezetimibe—atherosclerosis	0.000126	0.00119	CcSEcCtD
Sunitinib—Hypersensitivity—Pravastatin—atherosclerosis	0.000125	0.00119	CcSEcCtD
Sunitinib—Dizziness—Simvastatin—atherosclerosis	0.000125	0.00118	CcSEcCtD
Sunitinib—Rash—Ezetimibe—atherosclerosis	0.000125	0.00118	CcSEcCtD
Sunitinib—Dermatitis—Ezetimibe—atherosclerosis	0.000124	0.00118	CcSEcCtD
Sunitinib—Asthenia—Niacin—atherosclerosis	0.000124	0.00117	CcSEcCtD
Sunitinib—YES1—liver—atherosclerosis	0.000124	0.00123	CbGeAlD
Sunitinib—Headache—Ezetimibe—atherosclerosis	0.000124	0.00117	CcSEcCtD
Sunitinib—STK10—liver—atherosclerosis	0.000123	0.00122	CbGeAlD
Sunitinib—Pruritus—Niacin—atherosclerosis	0.000122	0.00116	CcSEcCtD
Sunitinib—TAOK3—liver—atherosclerosis	0.000122	0.00122	CbGeAlD
Sunitinib—Asthenia—Pravastatin—atherosclerosis	0.000122	0.00116	CcSEcCtD
Sunitinib—PDGFRA—liver—atherosclerosis	0.000122	0.00121	CbGeAlD
Sunitinib—Pruritus—Pravastatin—atherosclerosis	0.000121	0.00114	CcSEcCtD
Sunitinib—Vomiting—Simvastatin—atherosclerosis	0.00012	0.00113	CcSEcCtD
Sunitinib—Nausea—Lovastatin—atherosclerosis	0.00012	0.00113	CcSEcCtD
Sunitinib—CYP3A7-CYP3A51P—liver—atherosclerosis	0.00012	0.00119	CbGeAlD
Sunitinib—Rash—Simvastatin—atherosclerosis	0.000119	0.00112	CcSEcCtD
Sunitinib—Dermatitis—Simvastatin—atherosclerosis	0.000119	0.00112	CcSEcCtD
Sunitinib—Diarrhoea—Niacin—atherosclerosis	0.000118	0.00112	CcSEcCtD
Sunitinib—Headache—Simvastatin—atherosclerosis	0.000118	0.00112	CcSEcCtD
Sunitinib—Nausea—Ezetimibe—atherosclerosis	0.000117	0.00111	CcSEcCtD
Sunitinib—Diarrhoea—Pravastatin—atherosclerosis	0.000117	0.0011	CcSEcCtD
Sunitinib—Dizziness—Niacin—atherosclerosis	0.000114	0.00108	CcSEcCtD
Sunitinib—Dizziness—Pravastatin—atherosclerosis	0.000113	0.00107	CcSEcCtD
Sunitinib—Nausea—Simvastatin—atherosclerosis	0.000112	0.00106	CcSEcCtD
Sunitinib—Vomiting—Niacin—atherosclerosis	0.00011	0.00104	CcSEcCtD
Sunitinib—KDR—liver—atherosclerosis	0.00011	0.00109	CbGeAlD
Sunitinib—MAP2K5—liver—atherosclerosis	0.00011	0.00109	CbGeAlD
Sunitinib—Rash—Niacin—atherosclerosis	0.000109	0.00103	CcSEcCtD
Sunitinib—Dermatitis—Niacin—atherosclerosis	0.000109	0.00103	CcSEcCtD
Sunitinib—Headache—Niacin—atherosclerosis	0.000108	0.00103	CcSEcCtD
Sunitinib—Vomiting—Pravastatin—atherosclerosis	0.000108	0.00102	CcSEcCtD
Sunitinib—ABCC4—adipose tissue—atherosclerosis	0.000108	0.00107	CbGeAlD
Sunitinib—Rash—Pravastatin—atherosclerosis	0.000107	0.00102	CcSEcCtD
Sunitinib—Dermatitis—Pravastatin—atherosclerosis	0.000107	0.00101	CcSEcCtD
Sunitinib—CSF1R—liver—atherosclerosis	0.000107	0.00106	CbGeAlD
Sunitinib—Headache—Pravastatin—atherosclerosis	0.000107	0.00101	CcSEcCtD
Sunitinib—Nausea—Niacin—atherosclerosis	0.000103	0.000972	CcSEcCtD
Sunitinib—Nausea—Pravastatin—atherosclerosis	0.000101	0.000957	CcSEcCtD
Sunitinib—KIT—liver—atherosclerosis	9.71e-05	0.000966	CbGeAlD
Sunitinib—KCNH2—cardiovascular system—atherosclerosis	9.69e-05	0.000964	CbGeAlD
Sunitinib—ABCB1—blood vessel—atherosclerosis	9.53e-05	0.000948	CbGeAlD
Sunitinib—PDGFRB—liver—atherosclerosis	9.49e-05	0.000943	CbGeAlD
Sunitinib—ABCG2—adipose tissue—atherosclerosis	7.6e-05	0.000756	CbGeAlD
Sunitinib—ABCC4—liver—atherosclerosis	7.55e-05	0.000751	CbGeAlD
Sunitinib—ABCC2—liver—atherosclerosis	7.31e-05	0.000727	CbGeAlD
Sunitinib—CYP3A5—adipose tissue—atherosclerosis	7.06e-05	0.000702	CbGeAlD
Sunitinib—ABCG2—liver—atherosclerosis	5.33e-05	0.00053	CbGeAlD
Sunitinib—CYP3A5—liver—atherosclerosis	4.95e-05	0.000492	CbGeAlD
Sunitinib—ABCB1—cardiovascular system—atherosclerosis	4.25e-05	0.000423	CbGeAlD
Sunitinib—ABCB1—adipose tissue—atherosclerosis	3.75e-05	0.000373	CbGeAlD
Sunitinib—CYP3A4—liver—atherosclerosis	3.72e-05	0.000369	CbGeAlD
Sunitinib—ABCB1—liver—atherosclerosis	2.63e-05	0.000261	CbGeAlD
Sunitinib—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	7.75e-07	4.38e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—MAPK3—atherosclerosis	7.74e-07	4.38e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PPARA—atherosclerosis	7.74e-07	4.38e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—STAT3—atherosclerosis	7.73e-07	4.37e-06	CbGpPWpGaD
Sunitinib—YES1—Immune System—AKT1—atherosclerosis	7.71e-07	4.36e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—STAT3—atherosclerosis	7.71e-07	4.36e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—MAPK3—atherosclerosis	7.7e-07	4.36e-06	CbGpPWpGaD
Sunitinib—TYK2—Immune System—IL6—atherosclerosis	7.69e-07	4.35e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MAPK8—atherosclerosis	7.69e-07	4.35e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—NFKB1—atherosclerosis	7.68e-07	4.35e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—NFKB1—atherosclerosis	7.68e-07	4.35e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—NOS3—atherosclerosis	7.68e-07	4.34e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—NOS3—atherosclerosis	7.61e-07	4.3e-06	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—IL6—atherosclerosis	7.6e-07	4.3e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—IL6—atherosclerosis	7.58e-07	4.29e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—NOS3—atherosclerosis	7.56e-07	4.28e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MAPK8—atherosclerosis	7.55e-07	4.27e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MAPK8—atherosclerosis	7.55e-07	4.27e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—TGFB1—atherosclerosis	7.51e-07	4.25e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—IL6—atherosclerosis	7.51e-07	4.25e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CXCL8—atherosclerosis	7.5e-07	4.25e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—AGT—atherosclerosis	7.49e-07	4.24e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ALOX5—atherosclerosis	7.49e-07	4.23e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—TGFB1—atherosclerosis	7.47e-07	4.23e-06	CbGpPWpGaD
Sunitinib—KIT—Immune System—IL6—atherosclerosis	7.46e-07	4.22e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—IL6—atherosclerosis	7.46e-07	4.22e-06	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—AKT1—atherosclerosis	7.45e-07	4.21e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—VEGFA—atherosclerosis	7.41e-07	4.19e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—MAPK3—atherosclerosis	7.39e-07	4.18e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MMP9—atherosclerosis	7.37e-07	4.17e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—MAPK3—atherosclerosis	7.36e-07	4.16e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MMP9—atherosclerosis	7.35e-07	4.16e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—APOE—atherosclerosis	7.34e-07	4.15e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—STAT3—atherosclerosis	7.33e-07	4.15e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CXCL8—atherosclerosis	7.32e-07	4.14e-06	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—AKT1—atherosclerosis	7.31e-07	4.14e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—NFKB1—atherosclerosis	7.29e-07	4.13e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—NFKB1—atherosclerosis	7.27e-07	4.12e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—CAV1—atherosclerosis	7.27e-07	4.11e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—APOA1—atherosclerosis	7.26e-07	4.11e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—HMOX1—atherosclerosis	7.23e-07	4.09e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—VEGFA—atherosclerosis	7.19e-07	4.07e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MAPK8—atherosclerosis	7.17e-07	4.06e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TGFB1—atherosclerosis	7.17e-07	4.06e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MAPK8—atherosclerosis	7.15e-07	4.05e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—TGFB1—atherosclerosis	7.14e-07	4.04e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—IL6—atherosclerosis	7.14e-07	4.04e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—STAT3—atherosclerosis	7.12e-07	4.03e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—IL6—atherosclerosis	7.1e-07	4.02e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—VEGFA—atherosclerosis	7.1e-07	4.02e-06	CbGpPWpGaD
Sunitinib—TYK2—Immune System—AKT1—atherosclerosis	7.1e-07	4.01e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—IL6—atherosclerosis	7.08e-07	4.01e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—IL6—atherosclerosis	7.06e-07	4e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CXCL8—atherosclerosis	7.06e-07	3.99e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—STAT3—atherosclerosis	7.03e-07	3.98e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CXCL8—atherosclerosis	7.02e-07	3.97e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PTGS2—atherosclerosis	7.02e-07	3.97e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—IL6—atherosclerosis	7.01e-07	3.97e-06	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—AKT1—atherosclerosis	7.01e-07	3.96e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—MAPK3—atherosclerosis	7.01e-07	3.96e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—AKT1—atherosclerosis	6.99e-07	3.95e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—VEGFA—atherosclerosis	6.97e-07	3.95e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—VEGFA—atherosclerosis	6.97e-07	3.95e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PTGS2—atherosclerosis	6.96e-07	3.94e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—AKT1—atherosclerosis	6.93e-07	3.92e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—APOB—atherosclerosis	6.92e-07	3.92e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—STAT3—atherosclerosis	6.91e-07	3.91e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—STAT3—atherosclerosis	6.91e-07	3.91e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—IL6—atherosclerosis	6.89e-07	3.9e-06	CbGpPWpGaD
Sunitinib—KIT—Immune System—AKT1—atherosclerosis	6.88e-07	3.89e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—AKT1—atherosclerosis	6.88e-07	3.89e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—IL6—atherosclerosis	6.88e-07	3.89e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—MAPK3—atherosclerosis	6.8e-07	3.85e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TGFB1—atherosclerosis	6.8e-07	3.85e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MMP9—atherosclerosis	6.79e-07	3.84e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—GSTM1—atherosclerosis	6.73e-07	3.81e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MAPK3—atherosclerosis	6.72e-07	3.8e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—NFKB1—atherosclerosis	6.72e-07	3.8e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—NAMPT—atherosclerosis	6.71e-07	3.8e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CXCL8—atherosclerosis	6.71e-07	3.8e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—IL6—atherosclerosis	6.68e-07	3.78e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—LIPC—atherosclerosis	6.67e-07	3.77e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—APOC3—atherosclerosis	6.63e-07	3.75e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—IL6—atherosclerosis	6.63e-07	3.75e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PIK3CG—atherosclerosis	6.63e-07	3.75e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MMP9—atherosclerosis	6.62e-07	3.75e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—VEGFA—atherosclerosis	6.62e-07	3.74e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—LPL—atherosclerosis	6.61e-07	3.74e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—VEGFA—atherosclerosis	6.6e-07	3.73e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MAPK8—atherosclerosis	6.6e-07	3.73e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TGFB1—atherosclerosis	6.6e-07	3.73e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MAPK3—atherosclerosis	6.6e-07	3.73e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MAPK3—atherosclerosis	6.6e-07	3.73e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—LDLR—atherosclerosis	6.59e-07	3.73e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—IL6—atherosclerosis	6.58e-07	3.72e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—AKT1—atherosclerosis	6.58e-07	3.72e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—STAT3—atherosclerosis	6.55e-07	3.71e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—NFKB1—atherosclerosis	6.55e-07	3.71e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—AKT1—atherosclerosis	6.55e-07	3.71e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—IL6—atherosclerosis	6.54e-07	3.7e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—STAT3—atherosclerosis	6.54e-07	3.7e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—AKT1—atherosclerosis	6.53e-07	3.7e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—IL6—atherosclerosis	6.52e-07	3.69e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—IL6—atherosclerosis	6.52e-07	3.69e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TGFB1—atherosclerosis	6.52e-07	3.69e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—AKT1—atherosclerosis	6.52e-07	3.69e-06	CbGpPWpGaD
Sunitinib—JAK2—GPCR downstream signaling—AKT1—atherosclerosis	6.48e-07	3.67e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—AKT1—atherosclerosis	6.47e-07	3.66e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—GPX1—atherosclerosis	6.45e-07	3.65e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MAPK8—atherosclerosis	6.44e-07	3.64e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CETP—atherosclerosis	6.44e-07	3.64e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TGFB1—atherosclerosis	6.4e-07	3.62e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TGFB1—atherosclerosis	6.4e-07	3.62e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PPARG—atherosclerosis	6.39e-07	3.62e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MMP9—atherosclerosis	6.38e-07	3.61e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—IL6—atherosclerosis	6.38e-07	3.61e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—IL6—atherosclerosis	6.38e-07	3.61e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—IL6—atherosclerosis	6.38e-07	3.61e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—IL6—atherosclerosis	6.36e-07	3.6e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—AKT1—atherosclerosis	6.35e-07	3.59e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MMP9—atherosclerosis	6.35e-07	3.59e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—AKT1—atherosclerosis	6.35e-07	3.59e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—NFKB1—atherosclerosis	6.32e-07	3.57e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—NFKB1—atherosclerosis	6.28e-07	3.55e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—CD36—atherosclerosis	6.28e-07	3.55e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—INS—atherosclerosis	6.27e-07	3.55e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MAPK3—atherosclerosis	6.26e-07	3.54e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MAPK3—atherosclerosis	6.25e-07	3.53e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—IL6—atherosclerosis	6.22e-07	3.52e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MAPK8—atherosclerosis	6.21e-07	3.51e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MAPK8—atherosclerosis	6.18e-07	3.49e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—SCARB1—atherosclerosis	6.16e-07	3.49e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—AKT1—atherosclerosis	6.16e-07	3.48e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—IL6—atherosclerosis	6.13e-07	3.47e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—AKT1—atherosclerosis	6.11e-07	3.46e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—IL6—atherosclerosis	6.1e-07	3.45e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—VEGFA—atherosclerosis	6.1e-07	3.45e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TGFB1—atherosclerosis	6.08e-07	3.44e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—AKT1—atherosclerosis	6.07e-07	3.44e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MMP9—atherosclerosis	6.07e-07	3.43e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TGFB1—atherosclerosis	6.06e-07	3.43e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—STAT3—atherosclerosis	6.04e-07	3.41e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—AKT1—atherosclerosis	6.03e-07	3.41e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—IL6—atherosclerosis	6.02e-07	3.41e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—AKT1—atherosclerosis	6.02e-07	3.4e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—AKT1—atherosclerosis	6.02e-07	3.4e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—NFKB1—atherosclerosis	6e-07	3.4e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—MTHFR—atherosclerosis	5.95e-07	3.37e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—VEGFA—atherosclerosis	5.95e-07	3.36e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MAPK8—atherosclerosis	5.9e-07	3.34e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—AKT1—atherosclerosis	5.89e-07	3.33e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—STAT3—atherosclerosis	5.89e-07	3.33e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—AKT1—atherosclerosis	5.89e-07	3.33e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—AKT1—atherosclerosis	5.89e-07	3.33e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—IL6—atherosclerosis	5.87e-07	3.32e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—AKT1—atherosclerosis	5.87e-07	3.32e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PPARA—atherosclerosis	5.84e-07	3.3e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—IL6—atherosclerosis	5.83e-07	3.3e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—HMGCR—atherosclerosis	5.82e-07	3.29e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MAPK3—atherosclerosis	5.77e-07	3.26e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—ALB—atherosclerosis	5.75e-07	3.25e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—AKT1—atherosclerosis	5.74e-07	3.25e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—VEGFA—atherosclerosis	5.73e-07	3.24e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—VEGFA—atherosclerosis	5.7e-07	3.23e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—STAT3—atherosclerosis	5.68e-07	3.21e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—IL6—atherosclerosis	5.66e-07	3.2e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—AKT1—atherosclerosis	5.66e-07	3.2e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—AGT—atherosclerosis	5.65e-07	3.2e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—STAT3—atherosclerosis	5.65e-07	3.19e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—IL6—atherosclerosis	5.63e-07	3.19e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—AKT1—atherosclerosis	5.63e-07	3.18e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MAPK3—atherosclerosis	5.63e-07	3.18e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TGFB1—atherosclerosis	5.59e-07	3.16e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—AKT1—atherosclerosis	5.55e-07	3.14e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—APOE—atherosclerosis	5.54e-07	3.13e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—NOS3—atherosclerosis	5.5e-07	3.11e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—CAV1—atherosclerosis	5.49e-07	3.1e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—APOA1—atherosclerosis	5.48e-07	3.1e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TGFB1—atherosclerosis	5.46e-07	3.09e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—VEGFA—atherosclerosis	5.45e-07	3.08e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MAPK3—atherosclerosis	5.42e-07	3.07e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—AKT1—atherosclerosis	5.42e-07	3.07e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—IL6—atherosclerosis	5.4e-07	3.06e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—STAT3—atherosclerosis	5.4e-07	3.05e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MAPK3—atherosclerosis	5.39e-07	3.05e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—IL6—atherosclerosis	5.38e-07	3.04e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—AKT1—atherosclerosis	5.38e-07	3.04e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TGFB1—atherosclerosis	5.26e-07	2.98e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TGFB1—atherosclerosis	5.23e-07	2.96e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—AKT1—atherosclerosis	5.22e-07	2.96e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—AKT1—atherosclerosis	5.2e-07	2.94e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ABCA1—atherosclerosis	5.19e-07	2.94e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MAPK3—atherosclerosis	5.16e-07	2.92e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—IL6—atherosclerosis	5.12e-07	2.9e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PTGS2—atherosclerosis	5.03e-07	2.85e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TGFB1—atherosclerosis	5e-07	2.83e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PIK3CG—atherosclerosis	5e-07	2.83e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—AKT1—atherosclerosis	4.98e-07	2.82e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—IL6—atherosclerosis	4.97e-07	2.81e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—AKT1—atherosclerosis	4.97e-07	2.81e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—IL6—atherosclerosis	4.91e-07	2.78e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PPARG—atherosclerosis	4.83e-07	2.73e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—IL6—atherosclerosis	4.82e-07	2.73e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—IL6—atherosclerosis	4.82e-07	2.73e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—INS—atherosclerosis	4.73e-07	2.68e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—AKT1—atherosclerosis	4.73e-07	2.67e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—AKT1—atherosclerosis	4.59e-07	2.6e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—IL6—atherosclerosis	4.58e-07	2.59e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—IL6—atherosclerosis	4.57e-07	2.58e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—AKT1—atherosclerosis	4.53e-07	2.56e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—HMOX1—atherosclerosis	4.45e-07	2.52e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—AKT1—atherosclerosis	4.45e-07	2.52e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—AKT1—atherosclerosis	4.45e-07	2.52e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—ALB—atherosclerosis	4.34e-07	2.45e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—APOB—atherosclerosis	4.26e-07	2.41e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—AKT1—atherosclerosis	4.22e-07	2.39e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—IL6—atherosclerosis	4.22e-07	2.38e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—AKT1—atherosclerosis	4.21e-07	2.38e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—NOS3—atherosclerosis	4.15e-07	2.35e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GSTM1—atherosclerosis	4.15e-07	2.35e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—IL6—atherosclerosis	4.11e-07	2.33e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—LPL—atherosclerosis	4.07e-07	2.3e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GPX1—atherosclerosis	3.97e-07	2.25e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—IL6—atherosclerosis	3.97e-07	2.24e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—IL6—atherosclerosis	3.94e-07	2.23e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—AKT1—atherosclerosis	3.89e-07	2.2e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CD36—atherosclerosis	3.87e-07	2.19e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PTGS2—atherosclerosis	3.8e-07	2.15e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—AKT1—atherosclerosis	3.8e-07	2.15e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—IL6—atherosclerosis	3.77e-07	2.13e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—MTHFR—atherosclerosis	3.67e-07	2.07e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—AKT1—atherosclerosis	3.66e-07	2.07e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—AKT1—atherosclerosis	3.64e-07	2.06e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PPARA—atherosclerosis	3.6e-07	2.03e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—AKT1—atherosclerosis	3.53e-07	2e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—AKT1—atherosclerosis	3.5e-07	1.98e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—AGT—atherosclerosis	3.48e-07	1.97e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—AKT1—atherosclerosis	3.48e-07	1.97e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—APOE—atherosclerosis	3.41e-07	1.93e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CAV1—atherosclerosis	3.38e-07	1.91e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—APOA1—atherosclerosis	3.37e-07	1.91e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PIK3CG—atherosclerosis	3.08e-07	1.74e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PPARG—atherosclerosis	2.97e-07	1.68e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—INS—atherosclerosis	2.92e-07	1.65e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ALB—atherosclerosis	2.67e-07	1.51e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—NOS3—atherosclerosis	2.56e-07	1.45e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—AKT1—atherosclerosis	2.53e-07	1.43e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTGS2—atherosclerosis	2.34e-07	1.32e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—AKT1—atherosclerosis	1.91e-07	1.08e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—AKT1—atherosclerosis	1.18e-07	6.65e-07	CbGpPWpGaD
